A 4-year-old boy developed post-infectious glomerulonephritis (PIGN) and later atypical hemolytic uremic syndrome (aHUS), both of which affect the kidneys, but once doctors started treatment with the complement inhibitor Soliris (eculizumab), his blood problems resolved, his kidney function recovered, and he achieved long-term remission. “This case shows that…
News
A rare case of atypical hemolytic uremic syndrome (aHUS) developed after a kidney transplant in a young man and was successfully treated with Soliris (eculizumab), according to a case study. “The occurrence of [aHUS] following [kidney] transplantation is extremely uncommon and associated with adverse outcomes, often resulting in…
A teenage boy who was diagnosed in childhood with atypical hemolytic uremic syndrome (aHUS) was later found to also have Fabry disease and an inherited heart condition called hypertrophic cardiomyopathy — what researchers described as an “unusual trilogy” of rare diseases. The two additional genetic conditions were identified…
Treatment with Soliris (eculizumab), along with several immune-suppressing medications, was part of a treatment strategy that supported a woman with atypical hemolytic uremic syndrome (aHUS) in receiving a kidney donated from her mother — even though testing showed the two were not fully immunologically compatible. The case was…
Doctors successfully used a combination of Ultomiris (ravulizumab) and a blood pressure medication called sacubitril/valsartan to manage a case of atypical hemolytic uremic syndrome (aHUS) complicated by extremely high blood pressure. Researchers said it was the first reported case of the treatment combo being used to manage aHUS…
Prompt and intensive supportive care, which included plasma exchange and Soliris (eculizumab), successfully reversed organ failure and controlled atypical hemolytic uremic syndrome (aHUS) triggered by sepsis — a severe infection that can trigger widespread inflammation in the body — in a young…
Researchers have identified a potential gene therapy approach for atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G), two kidney diseases driven by overactive complement activity, according to a new mouse study. In mouse models of both diseases, delivering the gene for the complement protein factor D to liver…
The safety and effectiveness of Ultomiris (ravulizumab-cwvz) as a maintenance therapy for children and adolescents with atypical hemolytic uremic syndrome (aHUS) remained unchanged even when the drug was administered at lower doses, not using the patient’s weight as a guide. That’s according to a new, small study that…
Leakage in an artificial heart valve appeared to trigger atypical hemolytic uremic syndrome (aHUS) in a 70-year-old woman who had no disease-related genetic mutations, a team of researchers noted in a new report, saying the case highlights the importance of a full examination for individuals suspected of having the…
Researchers reported that atypical hemolytic uremic syndrome (aHUS) is driven by abnormal activation of the alternative complement pathway, an immune response that’s independent of antibody activity, according to a study using endothelial cells that line blood vessels. These results challenge a recent report suggesting that aHUS…
Recent Posts
- Boy’s kidney issues resolve after Soliris treatment: Case report
- I’m learning to say, ‘There’s always tomorrow’ when I’m feeling guilty
- Rare aHUS after kidney transplant successfully treated with Soliris
- Study describes ‘unusual trilogy’ of aHUS, Fabry disease, heart disorder
- My complicated health journey now includes post-exertional malaise
- Soliris part of strategy for complex kidney transplant in aHUS case
- My community helps me navigate the ultra-rare reality of living with aHUS
- Dual therapy manages aHUS with high blood pressure: Case report
- Caregivers are the unsung heroes of the rare disease world
- aHUS drug Soliris helps reverse organ failure in young woman in rare case